Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumati Gupta

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|February 22, 2016
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocationSumati Gupta, Launce Gouw, Jennifer Wright, et al.
Oncotarget|March 9, 2018
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cellsSumati Gupta, Kelly Doyle, Timothy L Mosbruger, et al.
Clinical Genitourinary Cancer|January 30, 2017
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without PrednisoneDavid Gill, David Gaston, Erin Bailey, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 2, 2026
Allostatic load, multimorbidity, and overall and cancer-specific survival among older adults in the United StatesJessica van Onselen, Maci Winn, Ainhoa Gomez-Lumbreras, et al.
The American Journal of Hospice & Palliative Care|May 28, 2021
Preoperative Advance Care Planning for Older Adults Undergoing Major Abdominal SurgeryJosh Bleicher, Lauren E McGuire, Riann B Robbins, et al.
Cancer Chemotherapy and Pharmacology|January 1, 2016
A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarinNeeraj Agarwal, Jordan P McPherson, Hanna Bailey, et al.
Future Oncology (London, England)|July 29, 2024
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United StatesUmang Swami, Agnes Hong, Brandon Diessner, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2016
A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumorsHanna Bailey, Jordan P McPherson, Erin B Bailey, et al.
BMC Research Notes|February 16, 2023
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)Matthew Gumbleton, Stephanie Allan, Hannah Conway, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2025
A Phase 2 Trial of Radium<sup>223</sup> and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR StudyJonathan Tward, Shane Lloyd, Skyler Johnson, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|February 22, 2016
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocationSumati Gupta, Launce Gouw, Jennifer Wright, et al.
Oncotarget|March 9, 2018
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cellsSumati Gupta, Kelly Doyle, Timothy L Mosbruger, et al.
Clinical Genitourinary Cancer|January 30, 2017
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without PrednisoneDavid Gill, David Gaston, Erin Bailey, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 2, 2026
Allostatic load, multimorbidity, and overall and cancer-specific survival among older adults in the United StatesJessica van Onselen, Maci Winn, Ainhoa Gomez-Lumbreras, et al.
The American Journal of Hospice & Palliative Care|May 28, 2021
Preoperative Advance Care Planning for Older Adults Undergoing Major Abdominal SurgeryJosh Bleicher, Lauren E McGuire, Riann B Robbins, et al.
Cancer Chemotherapy and Pharmacology|January 1, 2016
A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarinNeeraj Agarwal, Jordan P McPherson, Hanna Bailey, et al.
Future Oncology (London, England)|July 29, 2024
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United StatesUmang Swami, Agnes Hong, Brandon Diessner, et al.
Cancer Chemotherapy and Pharmacology|October 17, 2016
A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumorsHanna Bailey, Jordan P McPherson, Erin B Bailey, et al.
BMC Research Notes|February 16, 2023
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)Matthew Gumbleton, Stephanie Allan, Hannah Conway, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2025
A Phase 2 Trial of Radium<sup>223</sup> and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR StudyJonathan Tward, Shane Lloyd, Skyler Johnson, et al.
Pageof 7